May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Ophthalmological Changes in Patients With Benign Brain Tumors After Stereotactic Fractionated Radiotherapy
Author Affiliations & Notes
  • S.J. Froehlich
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • A.J. Mueller
    Department of Ophthalmology, Zentralklinikum, Augsburg, Germany
  • A.L. Grosu
    Department of Radiation Oncology, Technical University, Munich, Germany
  • Footnotes
    Commercial Relationships  S.J. Froehlich, None; A.J. Mueller, None; A.L. Grosu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 623. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.J. Froehlich, A.J. Mueller, A.L. Grosu; Ophthalmological Changes in Patients With Benign Brain Tumors After Stereotactic Fractionated Radiotherapy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):623.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Stereotactic fractionated radiotherapy (SFR) with a linear accelerator is an innovative and important option in the treatment strategy for patients with brain tumors. The method is characterized by a high precision in the delivery of the irradiation dose (total dose 50–56 Gy, single dose 1,8 Gy, 5x/week) and achieves a high local tumor control with a low rate of side effects. This study will show changes of ophthalmological functions in patients with benign brain tumors following SFR. Methods: We observed a total of 70 patients with brain tumors, 50 of them passed a mean follow–up time of 25 months after SFR. 49 patients (70%) had a meningioma, 14 (20%) a pituitary adenoma, 5 (7%) a craniopharyngioma and 2 (3%) other tumors. 51 patients (72%) underwent surgery prior to SFR, 19 (27%) did not. On every visit, best corrected visual acuity, perimetry (30° Humphrey, Goldmann outer margins), electrophysiology (VEP) and ophthalmoscopy (optic disc) were carried out. Results: 100 eyes from 50 patients passed a mean follow–up time of 25 months. Visual acuity was unchanged in 59 eyes (59%), improved in 24 eyes (24%) and got worse in 17 eyes (17%). At baseline, visual field was normal in 57 out of 140 eyes (41%) and pathological in 83 eyes (59%). During follow–up, perimetry revealed stable results in 74 eyes (74%), improvement in 24 eyes (24%) and deterioration in 2 eyes (2%). Visual evoked potentials were normal in 94 eyes at baseline (67%) and pathological in 46 eyes (33%). In 83 eyes (83%), VEP was unchanged after SFR, got better in 16 eyes (16%) and worse in just 1 case (1%). Optic disc was normal in 92 eyes (66%) and atrophic in 48 eyes (34%). This did not change during follow–up. Conclusions: Ophthalmological functions like visual field and visual evoked potentials were affected in just a few cases following treatment (2% respectively 1%). Involvement of optic disc did not change during follow–up, visual acuity was unchanged or improved in 83 eyes (83%). Thus, stereotactic fractionated radiotherapy represents a safe treatment option of benign brain tumors also regarding possible ophthalmological side effects even independent of prior surgeries.

Keywords: visual impairment: neuro-ophthalmological disease • electrophysiology: clinical • perimetry 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.